Supplementary Figure 5: rCela2a administration in vivo and in human islets. | Nature Genetics

Supplementary Figure 5: rCela2a administration in vivo and in human islets.

From: CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation

Supplementary Figure 5

a,b, Plasma insulin and glucose levels (mean ± s.e.m.) after intravenous administration of rCela2a to normoglycemic wild-type C57BL/6 mice (n = 5 in each group). Statistical analyses were carried out using two-sided Student’s t-test. *P < 0.05. c,d, Insulin and C-peptide secretion of human islets in response to WT-CELA2A. Response to KCl is used as a positive control and test of viability. Violin plots represent median, minimum and maximum. Statistical analyses were carried out using two-sided Student’s t-test per condition (n = 4). **P <0.01. e, Insulin secretion of human islets in response to WT-CELA2A (human) compared to rCela2a (mouse) represented in bar charts (mean ± s.e.m; n = 4 samples). Statistical analyses were carried out using two-sided Student’s t-test per conditions (***P <0.001). Response to KCl is used as a positive control and test of viability.

Back to article page